RxDoctor Payments Data

Jessica Hicks, APRN

Family · Ashland, KYNPI 1326308727

Payments from drug & device makers

$11,037in general payments, 2019–2025

Across 540 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$1K
  • Grifols USA, LLC$882
  • Sanofi$609
  • Actelion Pharmaceuticals US, Inc.$548
  • Novartis$433
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,995100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,037 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$11,871
Medicare patients
111
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter125$97,556
Dupixent PenDupilumab13$48,647
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,756
Spiriva RespimatTiotropium Bromide15$7,749
Breo ElliptaFluticasone/Vilanterol12$4,565
Albuterol Sulfate HfaAlbuterol Sulfate104$3,973
SymbicortBudesonide/Formoterol Fumarate11$3,281
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$1,866
Ventolin HfaAlbuterol Sulfate21$1,194
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,001
Prednisone106$246
Doxycycline Hyclate28$229
Montelukast Sodium21$225
Azithromycin13$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$3,054$102,121137 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,399$18,03827 claims
Boehringer IngelheimSpiriva Respimat$372$7,74915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →